The Footsie is rising but these FTSE 100 stocks still look cheap to me

The FTSE 100 has risen significantly over the past month, thanks to the development of vaccines. Stuart Blair looks at two FTSE 100 stocks he’d buy.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

One month ago, the FTSE 100 did not look like the most appealing place to invest. Coronavirus cases were at a record high and a second lockdown was starting in England. Fast-forward a though, and news of successful vaccines has greatly increased investor confidence. This has been reflected in the FTSE 100, which has risen a staggering 18% since the start of November. While I believe that many FTSE 100 stocks are now overpriced after this rise, there are still a number of opportunities in the market. These are my personal favourites.

A dividend stock

Aviva (LSE: AV) has bounced back well from the start of the crisis, with the insurance company posting resilient earnings and making some good business moves. For example, it is making good progress in simplifying the business and focusing on its core markets in the UK, Ireland and Canada. This has included the sale of both Aviva Singapore and Aviva Vita in Italy for a combined £2bn. Such simplification of the business will hopefully allow the company to grow profits, in turn increasing long-term shareholder value.

It may also seem ironic to call Aviva a dividend stock, despite the fact that it has cut its dividend by a third. But in comparison to other FTSE 100 stocks, a dividend yield of over 6% is extremely impressive. In addition, although disappointing to shareholders, the dividend cut seems very wise. Firstly, it will allow the insurer to deleverage, which in turn should strengthen the balance sheet. Secondly, it will also allow the group to increase the dividend in the years ahead. These increases are expected to be either low or mid-single-digits each year.

This FTSE 100 stock is still down 45% this year

BP (LSE: BP) is the other stock I think is far too cheap. Although oil prices remain very low, and problems still abound in the industry, BP shares do look set for a recovery. It has also been boosted by news of vaccines, which should help increase demand for oil.

But vaccines are not the only cause for optimism. For example, the third-quarter trading update was fairly positive, as shown by a profit of $100m. Although significantly lower than the $2.2bn last year, this is still a very good result in challenging conditions. Even more impressive was the fact that net debt has fallen to $40.4bn. This is compared to a figure of $46.5bn a year ago. While the gearing ratio is higher than the company will want, I am very encouraged by these figures.

Alongside its transition into greener energy, these recent results increase my confidence for a long-term recovery. Of course, the road to recovery will not be instant, but a dividend of over 6% should help satisfy investors for the short term. I’d therefore snap up this FTSE 100 stock now while it remains under 300p.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Stuart Blair owns shares in Aviva and BP. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »